Chimeron Bio

Executive Summary

Chimeron Bio is a privately held biotechnology company headquartered in Philadelphia, US, founded in 2015. The company is pioneering a novel class of genetic medicine centered on MultiPlex In-Vivo CAR-T therapy—a transformative approach that enables the delivery of complex, multi-gene therapeutic constructs directly into the body. By combining multiplex genetic engineering with in vivo delivery, Chimeron aims to overcome the limitations of ex vivo CAR-T manufacturing, potentially offering scalable, precise, and more accessible treatments for a wide range of diseases. The company's platform seeks to deliver multiple genetic modifications simultaneously within the patient's own cells, a feat previously considered impossible in vivo.

Upcoming Catalysts (preview)

• Q3 2026Series A financing round70% success
• Q4 2026IND submission for lead in-vivo CAR-T candidate50% success
• Q2 2026Preclinical data presentation at major conference (e.g., ASGCT)80% success